Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA.
about
Diabetes-related tuberculosis in the Middle East: an urgent need for regional research.Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice.Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA.Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania.Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014Understanding pharmacokinetics to improve tuberculosis treatment outcome.Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB.Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters.Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.The challenges of pharmacokinetic variability of first-line anti-TB drugs.Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough?Failure to reach therapeutic levels of rifampicin and isoniazid by recommended dosages.Performance of computed tomography versus chest radiography in patients with pulmonary tuberculosis with and without diabetes at a tertiary hospital in Riyadh, Saudi Arabia.Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar
P2860
Q26786671-25B6B7C7-AC45-49AB-8F86-82BA7CB0EDBCQ28543642-2D30A315-5B99-418D-BB3E-6B219B90B32BQ30274831-9DE67CB6-EE4E-40DB-9D60-E7FF9CCBF10DQ30274875-EA63BB49-8894-47D9-97CF-8BC462148CACQ30300207-28023D1C-E1E1-4215-B687-79950D82EBD7Q30411703-1E5C88AF-B538-4793-B827-01ED2AB60C08Q35746184-22C16B0F-5909-419D-9310-9B5A75DFD23DQ35778303-743B8FC9-1A2C-4C78-8B06-465A96CB9A21Q36268159-23C69526-FC15-4230-AA69-051A6D8B6A59Q36290609-96D79CDE-D9A2-4FB5-BEE0-F8DBBA47D8B8Q38865905-9BB4B4CA-8B18-4034-9E4F-7FB028ED34AAQ38977166-115739FB-B762-4833-A981-C420965E4860Q42688154-63271CD3-4EA4-43F9-8756-A77874656B82Q47954072-64B3244B-9F70-472D-BD41-46A7CC652CF4Q49326055-48C93D5E-C8E7-408E-BC56-B3B0A7EA3443Q56334454-F839C581-96C5-43CB-9326-C037B2712D05
P2860
Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Early Therapeutic Drug Monitor ...... Tuberculosis in Virginia, USA.
@ast
Early Therapeutic Drug Monitor ...... Tuberculosis in Virginia, USA.
@en
type
label
Early Therapeutic Drug Monitor ...... Tuberculosis in Virginia, USA.
@ast
Early Therapeutic Drug Monitor ...... Tuberculosis in Virginia, USA.
@en
prefLabel
Early Therapeutic Drug Monitor ...... Tuberculosis in Virginia, USA.
@ast
Early Therapeutic Drug Monitor ...... Tuberculosis in Virginia, USA.
@en
P2093
P2860
P356
P1476
Early Therapeutic Drug Monitor ...... Tuberculosis in Virginia, USA.
@en
P2093
Debbie Staley
Denise Dodge
Jane L Moore
P2860
P304
P356
10.1155/2013/129723
P577
2013-11-17T00:00:00Z